Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Proteomic and Biological Analysis of an In Vitro Human Endothelial System in Response to Drug Anaphylaxis

  • Yuste Montalvo, Alma
  • Fernandez Bravo, Sergio
  • Oliva, Tamara
  • Pastor Vargas, Carlos
  • Betancor, Diana
  • Goikoetxea, María José
  • Julio Laguna, José Julio
  • López, Juan Antonio
  • Alvarez Llamas, Gloria
  • Cuesta Herranz, Javier
  • Martin Lorenzo, Marta
  • Esteban, Vanesa
Anaphylaxis is a life-threatening systemic hypersensitivity reaction. During anaphylaxis, mediator release by effector cells causes endothelial barrier breakdown, increasing vascular permeability and leakage of fluids, which may lead to tissue edema. Although endothelial cells (ECs) are key players in this context, scant attention has been paid to the molecular analysis of the vascular system, and further analyses of this cell type are necessary, especially in humans. The protein expression pattern of human microvascular ECs was analyzed in response to sera from anaphylactic patients (EC-anaphylaxis) and sera from non-allergic subjects (EC-control) after 2 hours of contact. Firstly, a differential quantitative proteomic analysis of the protein extracts was performed by mass spectrometry using an isobaric labeling method. Second, the coordinated behavior of the identified proteins was analyzed using systems biology analysis (SBA). The proteome of the EC-anaphylaxis system showed 7,707 proteins, of which 1,069 were found to be significantly altered between the EC-control and EC-anaphylaxis groups (p-value < 0.05). Among them, a subproteome of 47 proteins presented a high rate of change (|ΔZq| ≥ 3). This panel offers an endothelial snapshot of the anaphylactic reaction. Those proteins with the highest individual changes in abundance were hemoglobin subunits and structural support proteins. The interacting network analysis of this altered subproteome revealed that the coagulation and complement systems are the main biological processes altered in the EC-anaphylactic system. The comprehensive SBA resulted in 5,512 functional subcategories (biological processes), 57 of which were significantly altered between EC-control and EC-anaphylaxis. The complement system, once again, was observed as the main process altered in the EC system created with serum from anaphylactic patients. Findings of the current study further our understanding of the underlying pathophysiological mechanisms operating in anaphylactic reactions. New target proteins and relevant signaling pathways operating in the in vitro endothelial-serum system have been identified. Interestingly, our results offer a protein overview of the micro-EC-anaphylaxis environment. The relevance of the coagulation, fibrinolytic, contact and complement systems in human anaphylaxis is described. Additionally, the untargeted high-throughput analysis used here is a novel approach that reveals new pathways in the study of the endothelial niche in anaphylaxis.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention

  • Martínez Santos, Paula
  • Baldán Martín, Montserrat
  • López, Juan A.
  • Martín Lorenzo, Marta
  • Santiago Hernández, Aránzazu
  • Agudiez, Marta
  • Cabrera Sierra, Martha
  • Calvo, Eva
  • Vázquez, Jesús
  • Ruiz Hurtado, Gema
  • Vivanco, Fernando
  • Ruilope Urioste, Luis Miguel
  • Barderas, María G.
  • Álvarez Llamas, Gloria
Background and aims The predictive value of traditional CV risk calculators is limited. Novel indicators of CVD progression are needed particularly in the young population. The main aim of this study was the identification of a molecular profile with added value to classical CV risk estimation. Methods: Eighty-one subjects (30–50 years) were classified in 3 groups according to their CV risk: healthy subjects; individuals with CV risk factors; and those who had suffered a previous CV event. The urine proteome was quantitatively analyzed and significantly altered proteins were identified between patients' groups, either related to CV risk or established organ damage. Target-MS and ELISA were used for confirmation in independent patients’ cohorts. Systems Biology Analysis (SBA) was carried out to identify functional categories behind CVD. Results: 4309 proteins were identified, 75 of them differentially expressed. ADX, ECP, FETUB, GDF15, GUAD and NOTCH1 compose a fingerprint positively correlating with lifetime risk estimate (LTR QRISK). Best performance ROC curve was obtained when ECP, GDF15 and GUAD were combined (AUC = 0.96). SBA revealed oxidative stress response, dilated cardiomyopathy, signaling by Wnt and proteasome, as main functional processes related to CV risk. Conclusions: A novel urinary protein signature is shown, which correlates with CV risk estimation in young individuals. Pending further confirmation, this six-protein-panel could help in CV risk assessment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Knowledge and practices regarding prostate cancer screening in Spanish men, The importance of personal and clinical characteristics (PROSHADE study)

  • Parker, Lucy A.
  • Caballero-Romeu, Juan-Pablo|||0000-0002-5737-6047
  • Chilet-Rosell, Elisa
  • Hernandez-Aguado, Ildefonso
  • Gómez-Pérez, Luis|||0000-0003-1396-0484
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Cebrián-Cuenca, Ana M.|||0000-0003-3710-6370
  • López-Garrigós, Maite
  • Moral Peláez, Irene|||0000-0002-3842-8796
  • Ronda, Elena
  • Gilabert, Mercedes
  • Canelo Aybar, Carlos Gilberto|||0000-0002-0844-4365
  • Párraga-Martínez, Ignacio
  • del Campo-Giménez, Maria
  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
Patients' decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening. A cross-sectional survey was conducted among men aged over 40, randomly sampled from the Spanish population, 2022. The survey underwent development and content validation using a modified Delphi method and was administered via telephone. Binomial logistic regression was used to explore the relationship between respondents' characteristics and participants' knowledge and practices concerning PCa and the PSA test. Out of 1,334 men, 1,067 (80%) respondents were interviewed with a mean age of 58.6 years (sd 11.9). Most had secondary or university studies (787, 73.8%) and 61 (5.7%) selfreported their health status as bad or very bad. Most of the respondents (1,018, 95.4%) had knowledge regarding PCa with nearly 70% expressed significant concern about its potential development (720, 70.8%), particularly among those under 64 years (p = 0.001). Out of 847 respondents, 573 (67.7%) reported that they have knowledge regarding the PSA test: 374 (65.4%) reported receiving information from a clinicians, 324 (86.6%) information about the benefits of the test and 189 (49,5%) about its risks, with differences based on educational background. In a multivariable analysis (adjusted for age, educational level and previous prostate problems), respondents with higher levels of education were more likely to have higher knowledge regarding the PSA test (OR 1.75, 95%CI 1.24-2.50, p<0.001). Although most of the patients reported to have knowledge regarding PCa, half of the interviewed men reported knowledge about PSA test. Differences in knowledge prostate cancer screening and undesirable consequences highlight the need to develop and provide tailored information for patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of patients' age and comorbidities on prostate cancer overdiagnosis in clinical practice

  • Beltrán, A.
  • Parker, L.
  • Moral-Pérez, I.
  • Caballero-Romeu, J.P.
  • Chilet-Rosell, E.
  • Hernández-Aguado, I.
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Ronda Pérez, Elena|||0000-0003-1886-466X
  • Gómez-Pérez, L.
  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
Introduction Overdiagnosis in PSA-based prostate cancer (PCa) screening is primarily studied in younger, healthier populations from clinical trials. This study aimed to evaluate the probability of overdiagnosis in PCa screening within a clinical practice context, focusing on its relationship with PSA levels, Gleason scores, and subsequent clinical procedures. Methods We conducted a retrospective cohort analysis of 1,070 asymptomatic men over 40 years old diagnosed with PCa between 2004 and 2022, following a positive PSA test. The patients were followed until December 31, 2022, with a median follow-up time of 5.7 years (IQR 3.2-8.6). The primary outcome was the probability of overdiagnosis, assessed through life expectancy and the Charlson Comorbidity Index, considering lead times of 5, 10, and 15 years. Results We found that patients with PSA levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Perspectives of clinicians and screening candidates on shared decision-making in prostate cancer screening with the prostate-specific antigen (PSA) test, A qualitative study (PROSHADE study)

  • Guilabert, Mercedes|||0000-0002-0706-9911
  • Parker, Lucy A.
  • Chilet-Rosell, Elisa
  • Gómez-Pérez, Luis|||0000-0003-1396-0484
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Cebrián-Cuenca, Ana M.|||0000-0003-3710-6370
  • López-Garrigós, Maite
  • Moral Peláez, Irene|||0000-0002-3842-8796
  • Ronda Pérez, Elena|||0000-0003-1886-466X
  • Canelo Aybar, Carlos Gilberto|||0000-0002-0844-4365
  • Hernández-Aguado, Ildefonso
  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
  • Sanchis, María José
  • Caballero-Romeu, Juan-Pablo|||0000-0002-5737-6047
  • Párraga Martínez, Ignacio
  • del Campo-Giménez, Maria
Objective The objective of this study is to analyse the perspectives of screening candidates and healthcare professionals on shared decision-making (SDM) in prostate cancer (PCa) screening using the prostate-specific antigen (PSA) test. Design Descriptive qualitative study (May-December 2022): six face-to-face focus groups and four semistructured interviews were conducted, transcribed verbatim and thematically analysed using ATLAS.ti software. Setting Data were obtained as part of the project PROSHADE (Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer) to develop a tool for SDM in PCa screening with PSA testing in Spain. Participants A total of 27 screening candidates (three groups of men: 40-50 years old; 51-60 years old and 61-80 years old), 25 primary care professionals (one group of eight nurses and two groups of physicians: one with more and one with less than 10 years of experience), and four urologists. Focus groups for patients and healthcare professionals were conducted separately. Main outcome measures Participants' perceptions of shared decision-making related to PSA opportunistic screening, including their understanding, preferences, and attitudes. Results Three themes were generated: (1) perceptions of SDM, (2) perceptions of PSA testing and (3) perceptions of SDM regarding PCa screening. Theme 1: screening candidates valued SDM when it included clear information and empowered them. There was consensus with primary care health professionals on this point, although their knowledge and implementation of SDM varied. Theme 2: candidates were divided on PSA testing; some trusted it for early detection, while others expressed scepticism due to concerns about false positives and invasive procedures, reflecting gaps in accessible information. Theme 3: Professionals across primary and specialised care stressed the need for standardised SDM protocols. Primary care physicians were particularly concerned that PSA decisions align with scientific evidence and urologists recognised SDM as valuable in PSA testing only if it was adequately explained to each patient. Barriers to implementing SDM included insufficient coordination across care levels, lack of consensus-driven protocols and limited clinical time. Conclusions While patients expect comprehensive information, primarily based on practice to achieve empowerment, healthcare professionals face obstacles such as limited time and insufficient coordination between primary care and urology. All stakeholders agree on the importance of evidence-based tools to reinforce effective SDM and enhance collaboration across urologists and primary care in the context of PSA testing.
Repisalud
Publicación Artículo científico (JournalArticle)

The Urinary Glycopeptide Profile Differentiates Early Cardiorenal Risk in Subjects Not Meeting Criteria for Chronic Kidney Disease.

  • Santiago-Hernandez, Aranzazu
  • Martin-Lorenzo, Marta
  • Gómez-Serrano, María
  • Lopez, Juan Antonio
  • Martin-Blazquez, Ariadna
  • Vellosillo, Perceval
  • Minguez, Pablo
  • Martinez, Paula J
  • Vázquez, Jesús
  • Ruiz-Hurtado, Gema
  • Barderas, Maria G
  • Sarafidis, Pantelis
  • Segura, Julian
  • Ruilope, Luis M
  • Alvarez-Llamas, Gloria
Early diagnosis and treatment of chronic kidney disease (CKD) is a worldwide challenge. Subjects with albumin-to-creatinine ratio (ACR) ≥ 30 mg/g and preserved renal function are considered to be at no cardiorenal risk in clinical practice, but prospective clinical studies evidence increased risk, even at the high-normal (HN) ACR range (10-30 mg/g), supporting the need to identify other molecular indicators for early assessment of patients at higher risk. Following our previous studies, here we aim to stratify the normoalbuminuria range according to cardiorenal risk and identify the glycoproteins and N-glycosylation sites associated with kidney damage in subclinical CKD. Glycoproteins were analyzed in urine from hypertensive patients within the HN ACR range compared to control group (C; ACR < 10 mg/g) by mass spectrometry. A different cohort was analyzed for confirmation (ELISA) and sex perspective was evaluated. Patients' follow-up for 8 years since basal urine collection revealed higher renal function decline and ACR progression for HN patients. Differential N-glycopeptides and their N -glycosylation sites were also identified, together with their pathogenicity. N-glycosylation may condition pathological protein deregulation, and a panel of 62 glycoproteins evidenced alteration in normoalbuminuric subjects within the HN range. Haptoglobin-related protein, haptoglobin, afamin, transferrin, and immunoglobulin heavy constant gamma 1 (IGHG1) and 2 (IGHG2) showed increased levels in HN patients, pointing to disturbed iron metabolism and tubular reabsorption and supporting the tubule as a target of interest in the early progression of CKD. When analyzed separately, haptoglobin, afamin, transferrin, and IGHG2 remained significant in HN, in both women and men. At the peptide level, 172 N-glycopeptides showed differential abundance in HN patients, and 26 showed high pathogenicity, 10 of them belonging to glycoproteins that do not show variation between HN and C groups. This study highlights the value of glycosylation in subjects not meeting KDIGO criteria for CKD. The identified N-glycopeptides and glycosylation sites showed novel targets, for both the early assessment of individual cardiorenal risk and for intervention aimed at anticipating CKD progression.
Repisalud
Publicación Artículo científico (JournalArticle)

Early renal and vascular damage within the normoalbuminuria condition.

  • Santiago-Hernandez, Aranzazu
  • Martin-Lorenzo, Marta
  • Martínez, Paula J
  • Gómez-Serrano, María
  • Lopez, Juan Antonio
  • Cannata, Pablo
  • Esteban, Vanesa
  • Heredero, Angeles
  • Aldamiz-Echevarria, Gonzalo
  • Vázquez, Jesús
  • Ruiz-Hurtado, Gema
  • Barderas, Maria G
  • Segura, Julian
  • Ruilope, Luis M
  • Alvarez-Llamas, Gloria
A continuous association between albuminuria and cardiorenal risk exists further below moderately increased albuminuria ranges. If only based in albumin to creatinine ratio (ACR) higher than 30 mg/g, a significant percentage of individuals may be out of the scope for therapeutic management. Despite epidemiological outcomes, the identification of biochemical changes linked to early albuminuria is underexplored, and normoalbuminuric individuals are usually considered at no risk in clinical practice. Here, we aimed to identify early molecular alterations behind albuminuria development. Hypertensive patients under renin-angiotensin system (RAS) suppression were classified as control, (ACR < 10 mg/g) or high-normal (ACR = 10-30 mg/g). Urinary protein alterations were quantified and confirmed by untargeted and targeted mass spectrometry. Coordinated protein responses with biological significance in albuminuria development were investigated. Immunohistochemistry assays were performed in human kidney and arterial tissue to in situ evaluate the associated damage. A total of 2663 identified proteins reflect inflammation, immune response, ion transport and lipids metabolism (P value ≤ 0.01). A1AT, VTDB and KNG1 varied in high-normal individuals (P value < 0.05), correlated with ACR and associated with the high-normal condition (odds ratio of 20.76, 6.00 and 7.04 were found, respectively (P value < 0.001)). After 12 months, protein variations persist and aggravate in progressors to moderately increased albuminuria. At tissue level, differential protein expression was found in kidney from individuals with moderately increased albuminuria and atherosclerotic aortas for the three proteins, confirming their capacity to reflect subclinical organ damage. Early renal and vascular damage is molecularly evidenced within the normoalbuminuria condition.
Repisalud
Publicación Artículo científico (JournalArticle)

Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension

  • Martin-Lorenzo, Marta
  • Martinez, Paula J
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Minguez, Pablo
  • Santiago-Hernandez, Aranzazu
  • Vazquez, Jesus
  • Segura, Julian
  • Ruiz-Hurtado, Gema
  • Vivanco, Fernando
  • Barderas, Maria G
  • Ruilope, Luis M
  • Alvarez-Llamas, Gloria
Resistant hypertension prevalence is progressively increasing, and prolonged exposure to suboptimal blood pressure control results in higher cardiovascular risk and end-organ damage. Among various antihypertensive agents, spironolactone seems the most effective choice to treat resistant hypertension once triple therapy including a diuretic fails. However success in blood pressure control is not guaranteed, adverse effects are not negligible, and no clinical tools are available to predict patient's response. Complementary to our previous study of resistant hypertension metabolism, here we investigated urinary proteome changes with potential capacity to predict response to spironolactone. Twenty-nine resistant hypertensives were included. A prospective study was conducted and basal urine was collected before spironolactone administration. Patients were classified in responders or nonresponders in terms of blood pressure control. Protein quantitation was performed by liquid chromatography-mass spectrometry; ELISA and target mass spectrometry analysis were performed for confirmation. Among 3310 identified proteins, HP (haptoglobin) and HPR (haptoglobin-related protein) showed the most significant variations, with increased levels in nonresponders compared with responders before drug administration (variation rate, 5.98 and 7.83, respectively). Protein-coordinated responses were also evaluated by functional enrichment analysis, finding oxidative stress, chronic inflammatory response, blood coagulation, complement activation, and regulation of focal adhesions as physiopathological mechanisms in resistant hypertension. In conclusion, protein changes able to predict patients' response to spironolactone in basal urine were here identified for the first time. These data, once further confirmed, will support clinical decisions on patients' management while contributing to optimize the rate of control of resistant hypertensives with spironolactone.
Repisalud
Publicación Artículo científico (JournalArticle)

Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria

  • Martin-Lorenzo, Marta
  • Gonzalez-Calero, Laura
  • Martinez, Paula J.
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Ruiz-Hurtado, Gema
  • de la Cuesta, Fernando
  • Segura, Julian
  • Vazquez, Jesus
  • Vivanco, Fernando
  • Barderas, Maria G
  • Ruilope, Luis M
  • Alvarez-Llamas, Gloria
Albuminuria development in hypertensive patients is an indicator of higher cardiovascular (CV) risk and renal damage. Chronic renin-angiotensin system (RAS) suppression facilitates blood pressure control but it does not prevent from albuminuria development. We pursued the identification of protein indicators in urine behind albuminuria development in hypertensive patients under RAS suppression. Urine was collected from 100 patients classified in three groups according to albuminuria development: (a) patients with persistent normoalbuminuria; (b) patients developing de novo albuminuria; (c) patients with maintained albuminuria. Quantitative analysis was performed in a first discovery cohort by isobaric labeling methodology. Alterations of proteins of interest were confirmed by target mass spectrometry analysis in an independent cohort. A total of 2416 proteins and 1223 functional categories (coordinated protein responses) were identified. Immune response, adhesion of immune and blood cells, and phagocytosis were found significantly altered in patients with albuminuria compared to normoalbuminuric individuals. The complement system C3 increases, while Annexin A1, CD44, S100A8 and S100A9 proteins showed significant diminishment in their urinary levels when albuminuria is present. This study reveals specific links between immune response and controlled hypertension in patients who develop albuminuria, pointing to potential protein targets for novel and future therapeutic interventions.
Repisalud
Publicación Artículo científico (JournalArticle)

Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria

  • Gonzalez-Calero, Laura
  • Martinez, Paula J.
  • Martin-Lorenzo, Marta
  • Baldan-Martin, Montserrat
  • Ruiz-Hurtado, Gema
  • de la Cuesta, Fernando
  • Calvo, Eva
  • Segura, Julian
  • Lopez, Juan Antonio
  • Vazquez, Jesus
  • Barderas, Maria G
  • Ruilope, Luis M
  • Vivanco, Fernando
  • Alvarez-Llamas, Gloria
Albuminuria is an indicator of cardiovascular risk and renal damage in hypertensive individuals. Chronic renin-angiotensin system (RAS) suppression facilitates blood pressure control and prevents development of new-onset-albuminuria. A significant number of patients, however, develop albuminuria despite chronic RAS blockade, and the physiopathological mechanisms are underexplored. Urinary exosomes reflect pathological changes taking place in the kidney. The objective of this work was to examine exosomal protein alterations in hypertensive patients with albuminuria in the presence of chronic RAS suppression, to find novel clues underlying its development. Patients were followed-up for three years and were classified as: a) patients with persistent normoalbuminuria; b) patients developing de novo albuminuria; and c) patients with maintained albuminuria. Exosomal protein alterations between groups were identified by isobaric tag quantitation (iTRAQ). Confirmation was approached by target analysis (SRM). In total, 487 proteins were identified with high confidence. Specifically, 48 proteins showed an altered pattern in response to hypertension and/or albuminuria. Out of them, 21 proteins interact together in three main functional clusters: glycosaminoglycan degradation, coagulation and complement system, and oxidative stress. The identified proteins constitute potential targets for drug development and may help to define therapeutic strategies to evade albuminuria progression in hypertensive patients chronically treated.
Repisalud
Publicación Artículo científico (JournalArticle)

Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention

  • Martínez, Paula J
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Martín-Lorenzo, Marta
  • Santiago-Hernández, Aránzazu
  • Agudiez, Marta
  • Cabrera, Martha
  • Calvo, Eva
  • Vazquez, Jesus
  • Ruiz-Hurtado, Gema
  • Vivanco, Fernando
  • Ruilope, Luis M
  • Barderas, Maria G
  • Alvarez-Llamas, Gloria
BACKGROUND AND AIMS: The predictive value of traditional CV risk calculators is limited. Novel indicators of CVD progression are needed particularly in the young population. The main aim of this study was the identification of a molecular profile with added value to classical CV risk estimation. METHODS: Eighty-one subjects (30-50 years) were classified in 3 groups according to their CV risk: healthy subjects; individuals with CV risk factors; and those who had suffered a previous CV event. The urine proteome was quantitatively analyzed and significantly altered proteins were identified between patients' groups, either related to CV risk or established organ damage. Target-MS and ELISA were used for confirmation in independent patients' cohorts. Systems Biology Analysis (SBA) was carried out to identify functional categories behind CVD. RESULTS: 4309 proteins were identified, 75 of them differentially expressed. ADX, ECP, FETUB, GDF15, GUAD and NOTCH1 compose a fingerprint positively correlating with lifetime risk estimate (LTR QRISK). Best performance ROC curve was obtained when ECP, GDF15 and GUAD were combined (AUC = 0.96). SBA revealed oxidative stress response, dilated cardiomyopathy, signaling by Wnt and proteasome, as main functional processes related to CV risk. CONCLUSIONS: A novel urinary protein signature is shown, which correlates with CV risk estimation in young individuals. Pending further confirmation, this six-protein-panel could help in CV risk assessment.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Perspectives of clinicians and screening candidates on shared decision-making in prostate cancer screening with the prostate-specific antigen (PSA) test: a qualitative study (PROSHADE study)

  • Sanchis, María Jose
  • Guilabert, Mercedes
  • Parker, Lucy Anne
  • Caballero-Romeu, Juan-Pablo
  • Chilet Rosell, Elisa
  • Gómez-Pérez, Luis
  • Alonso Coello, Pablo
  • Cebrián-Cuenca, Ana
  • López Garrigós, Maite
  • Moral-Peláez, Irene
  • Ronda-Pérez, Elena
  • Canelo-Aybar, Carlos
  • Hernández Aguado, Ildefonso
  • Párraga-Martínez, Ignacio
  • Campo-Giménez, María del
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Objective The objective of this study is to analyse the perspectives of screening candidates and healthcare professionals on shared decision-making (SDM) in prostate cancer (PCa) screening using the prostate-specific antigen (PSA) test. Design Descriptive qualitative study (May–December 2022): six face-to-face focus groups and four semistructured interviews were conducted, transcribed verbatim and thematically analysed using ATLAS.ti software. Setting Data were obtained as part of the project PROSHADE (Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer) to develop a tool for SDM in PCa screening with PSA testing in Spain. Participants A total of 27 screening candidates (three groups of men: 40–50 years old; 51–60 years old and 61–80 years old), 25 primary care professionals (one group of eight nurses and two groups of physicians: one with more and one with less than 10 years of experience), and four urologists. Focus groups for patients and healthcare professionals were conducted separately. Main outcome measures Participants' perceptions of shared decision-making related to PSA opportunistic screening, including their understanding, preferences, and attitudes. Results Three themes were generated: (1) perceptions of SDM, (2) perceptions of PSA testing and (3) perceptions of SDM regarding PCa screening. Theme 1: screening candidates valued SDM when it included clear information and empowered them. There was consensus with primary care health professionals on this point, although their knowledge and implementation of SDM varied. Theme 2: candidates were divided on PSA testing; some trusted it for early detection, while others expressed scepticism due to concerns about false positives and invasive procedures, reflecting gaps in accessible information. Theme 3: professionals across primary and specialised care stressed the need for standardised SDM protocols. Primary care physicians were particularly concerned that PSA decisions align with scientific evidence and urologists recognised SDM as valuable in PSA testing only if it was adequately explained to each patient. Barriers to implementing SDM included insufficient coordination across care levels, lack of consensus-driven protocols and limited clinical time. Conclusions While patients expect comprehensive information, primarily based on practice to achieve empowerment, healthcare professionals face obstacles such as limited time and insufficient coordination between primary care and urology. All stakeholders agree on the importance of evidence-based tools to reinforce effective SDM and enhance collaboration across urologists and primary care in the context of PSA testing.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Disparities in prostate cancer screening practices among general practitioners and urologists (PROSHADE study): A cross-sectional study

  • Lumbreras, Blanca
  • Parker, Lucy Anne
  • Alonso Coello, Pablo
  • Caballero-Romeu, Juan-Pablo
  • Párraga-Martínez, Ignacio
  • Prieto, Luis
  • Moral-Peláez, Irene
  • Campo-Giménez, María del
  • Gómez-Pérez, Luis
  • Cebrián-Cuenca, Ana
  • López Garrigós, Maite
  • Ronda-Pérez, Elena
  • Guilabert, Mercedes
  • Canelo-Aybar, Carlos
  • Hernández Aguado, Ildefonso
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Introduction: Recent European recommendations promote risk-based, patient-centred screening models that emphasise shared decision-making (SDM) in prostate cancer (PCa) screening with prostate-specific antigen (PSA) testing. Understanding how clinicians apply these practices is essential, particularly given the roles of general practitioners (GPs) and urologists in detection. The aim of this study was to compare the knowledge, attitudes, and practices of GPs and urologists in Spain regarding PSA testing, PCa screening, and SDM implementation. Methods: Cross-sectional survey conducted via an online questionnaire. Members of the Spanish Association of Urology (AEU) and the Spanish Society of Family and Community Medicine (semFYC) were surveyed online. The survey, developed and validated using a modified Delphi process, contained 18 items assessing clinicians’ opinions, practices, and knowledge of guidelines. Data from 494 respondents (280 GPs and 214 urologists) were analysed using descriptive statistics and logistic regression to explore differences between specialty, demographics, and screening practices. Results: Urologists were more likely than GPs to consider PSA testing important (97.2% vs. 83.2%) and useful (96% vs. 44.4%), and to recommend it to relatives (90.4% vs. 44%) (all p < 0.001). They reported to initiate testing earlier (50–59 years: 77.8% vs. 32%) and reported to perform it more frequently (annual testing: 60.7% vs. 45.6%, p < 0.001). GPs reported to more often engaged in SDM when ordering PSA tests (69.7% vs. 10%, p < 0.001). Knowledge of guidelines was higher among urologists (91% vs. 24.1%), yet 75.4% stated that they had not modified practice following updated recommendations. Conclusions: Significant specialty-based differences exist in PSA testing practices, perceptions, and guideline adherence. Urologists show greater familiarity with recommendations, while GPs reported more patient-centred communication.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Impact of patients’ age and comorbidities on prostate cancer overdiagnosis in clinical practice

  • Beltrán, Abraham
  • Parker, Lucy Anne
  • Moral-Peláez, Irene
  • Caballero-Romeu, Juan-Pablo
  • Chilet Rosell, Elisa
  • Hernández Aguado, Ildefonso
  • Alonso Coello, Pablo
  • Ronda-Pérez, Elena
  • Gómez-Pérez, Luis
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Introduction. Overdiagnosis in PSA-based prostate cancer (PCa) screening is primarily studied in younger, healthier populations from clinical trials. This study aimed to evaluate the probability of overdiagnosis in PCa screening within a clinical practice context, focusing on its relationship with PSA levels, Gleason scores, and subsequent clinical procedures. Methods. We conducted a retrospective cohort analysis of 1,070 asymptomatic men over 40 years old diagnosed with PCa between 2004 and 2022, following a positive PSA test. The patients were followed until December 31, 2022, with a median follow-up time of 5.7 years (IQR 3.2–8.6). The primary outcome was the probability of overdiagnosis, assessed through life expectancy and the Charlson Comorbidity Index, considering lead times of 5, 10, and 15 years. Results. We found that patients with PSA levels >10 ng/dL and/or Gleason scores ≥8 were generally older and had more comorbidities than those with PSA levels 4–10 ng/dL and/or Gleason scores ≤7. The probability of overdiagnosis was significantly higher in patients with PSA levels >10 ng/dL (41.4%, IQR 21.5–73.9) and Gleason scores ≥8 (42.6%, IQR 14.9–38.9), compared to those with PSA levels 4–10 ng/dL (20.1%, IQR 12.8–30.4) and Gleason scores ≤7 (26.6%, IQR 23.6–68.6). Notably, 71.7% of patients did not receive pharmacological treatment. Patients with higher PSA levels also experienced greater radiation exposure from diagnostic imaging (median 19.9 mSv vs. 14.7 mSv, p = 0.004). Conclusions. These findings underscore the high likelihood of overdiagnosis in older patients with elevated PSA levels and significant comorbidities, highlighting the need for careful consideration of patient comorbidities before PSA testing.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

PROSHADE Protocol: Designing and Evaluating a Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer: A Mix-Method Study

  • Lumbreras, Blanca
  • Parker, Lucy Anne
  • Alonso Coello, Pablo
  • Mira-Bernabeu, Javier
  • Gómez-Pérez, Luis
  • Caballero-Romeu, Juan-Pablo
  • Pertusa-Martínez, Salvador
  • Cebrián-Cuenca, Ana
  • Moral-Peláez, Irene
  • López Garrigós, Maite
  • Canelo-Aybar, Carlos
  • Ronda-Pérez, Elena
  • Guilabert, Mercedes
  • Prieto-González, Antonio
  • Hernández Aguado, Ildefonso
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Background: Opportunistic prostate-specific antigen (PSA) screening may reduce prostate cancer mortality risk but is associated with false positive results, biopsy complications and overdiagnosis. Although different organisations have emphasised the importance of shared decision making (SDM) to assist men in deciding whether to undergo prostate cancer screening, recent evaluations show that the available decision aids fail to facilitate SDM, mainly because they do not consider the patients’ perspective in their design. We aim to systematically develop and test a patient decision aid to promote SDM in prostate cancer screening, following the Knowledge to Action framework. Methods: (1) Feasibility study: a quantitative survey evaluating the population and clinician (urologists and general practitioners) knowledge of the benefits and risks derived from PSA determination and the awareness of the available recommendations. Focus groups to explore the challenges patients and clinicians face when discussing prostate cancer screening, the relevance of a decision aid and how best to integrate it into practice. (2) Patient decision aid development: Based on this data, an evidence-based multicomponent SDM patient decision aid will be developed. (3) User-testing: an assessment of the prototype of the initial patient decision aid through a user-testing design based on mix-methods (questionnaire and semi-structured review). The decision aid will be refined through several iterative cycles of feedback and redesign. (4) Validation: an evaluation of the patient decision aid through a cluster-randomised controlled trial. Discussion: The designed patient decision aid will provide balanced information on screening benefits and risks and should help patients to consider their personal preferences and to take a more active role in decision making. Conclusions: The well-designed patient decision aid (PDA) will provide balanced information on screening benefits and risks and help patients consider their personal preferences.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study)

  • Parker, Lucy Anne
  • Caballero-Romeu, Juan-Pablo
  • Chilet Rosell, Elisa
  • Hernández Aguado, Ildefonso
  • Gómez-Pérez, Luis
  • Alonso Coello, Pablo
  • Cebrián-Cuenca, Ana
  • López Garrigós, Maite
  • Moral-Peláez, Irene
  • Ronda-Pérez, Elena
  • Gilabert, Mercedes
  • Canelo-Aybar, Carlos
  • Párraga-Martínez, Ignacio
  • Campo-Giménez, María del
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Introduction Patients’ decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening. Methods A cross-sectional survey was conducted among men aged over 40, randomly sampled from the Spanish population, 2022. The survey underwent development and content validation using a modified Delphi method and was administered via telephone. Binomial logistic regression was used to explore the relationship between respondents’ characteristics and participants’ knowledge and practices concerning PCa and the PSA test. Results Out of 1,334 men, 1,067 (80%) respondents were interviewed with a mean age of 58.6 years (sd 11.9). Most had secondary or university studies (787, 73.8%) and 61 (5.7%) self-reported their health status as bad or very bad. Most of the respondents (1,018, 95.4%) had knowledge regarding PCa with nearly 70% expressed significant concern about its potential development (720, 70.8%), particularly among those under 64 years (p = 0.001). Out of 847 respondents, 573 (67.7%) reported that they have knowledge regarding the PSA test: 374 (65.4%) reported receiving information from a clinicians, 324 (86.6%) information about the benefits of the test and 189 (49,5%) about its risks, with differences based on educational background. In a multivariable analysis (adjusted for age, educational level and previous prostate problems), respondents with higher levels of education were more likely to have higher knowledge regarding the PSA test (OR 1.75, 95%CI 1.24–2.50, p<0.001). Conclusions Although most of the patients reported to have knowledge regarding PCa, half of the interviewed men reported knowledge about PSA test. Differences in knowledge prostate cancer screening and undesirable consequences highlight the need to develop and provide tailored information for patients.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Barriers and facilitators of shared decision-making in prostate cancer screening in primary care: A systematic review

  • Estevan-Vilar, María
  • Parker, Lucy Anne
  • Caballero-Romeu, Juan-Pablo
  • Ronda-Pérez, Elena
  • Hernández Aguado, Ildefonso
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Objective: To identify barriers and facilitators of the implementation of shared decision-making (SDM) on PSA testing in primary care. Design: Systematic review of articles. Data sources: PubMed, Scopus, Embase and Web of Science. Eligibility criteria: Original studies published in English or Spanish that assessed the barriers to and facilitators of SDM before PSA testing in primary care were included. No time restrictions were applied. Data extraction and synthesis: Two review authors screened the titles, abstracts and full texts for inclusion, and assessed the quality of the included studies. A thematic synthesis of the results were performed and developed a framework. Quality assessment of the studies was based on three checklists: STROBE for quantitative cross-sectional studies, GUIDED for intervention studies and SRQR for qualitative studies. Results: The search returned 431 articles, of which we included 13: five cross-sectional studies, two intervention studies, five qualitative studies and one mixed methods study. The identified barriers included lack of time (healthcare professionals), lack of knowledge (healthcare professionals and patients), and preestablished beliefs (patients). The identified facilitators included decision-making training for professionals, education for patients and healthcare professionals, and dissemination of information. Conclusions: SDM implementation in primary care seems to be a recent field. Many of the barriers identified are modifiable, and the facilitators can be leveraged to strengthen the implementation of SDM.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç
  • Bystrup, Sara
  • Cabrero-de Las Heras, Sara
  • Musulén, Eva
  • Palomero, Luis
  • Henar Alonso, Maria
  • Arango Corro, Diego
  • Nieto Raya, Rocio
Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker, Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo, Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu, In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease., This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Bystrup, Sara|||0000-0002-7971-0851
  • Cabrero de las Heras, Sara
  • Musulén, Eva|||0000-0002-9667-6464
  • Palomero, Luis|||0000-0002-9144-1017
  • Alonso, María Henar
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Arango, Diego|||0000-0003-2953-3284
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Queralt, C.|||0000-0001-9875-0173
  • Manzano Mozo, José Luís
  • Layos, Laura
  • Bugés, Cristina|||0000-0003-2013-1510
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

  • Bastard, Paul|||0000-0002-5926-8437
  • Rosen, Lindsey|||0000-0001-5894-3878
  • Zhang, Qian|||0000-0002-9040-3289
  • Michailidis, Eleftherios|||0000-0002-9907-4346
  • Hoffmann, Hans-Heinrich|||0000-0003-0554-0244
  • Zhang, Yu|||0000-0002-0332-0013
  • Dorgham, Karim|||0000-0001-9539-3203
  • Philippot, Quentin
  • Rosain, Jérémie|||0000-0002-2822-161X
  • Béziat, Vivien|||0000-0002-4020-824X
  • Manry, Jeremy|||0000-0001-5998-2051
  • Shaw, Elana|||0000-0001-9265-8026
  • Haljasmägi, Liis|||0000-0001-7162-9808
  • Peterson, Pärt|||0000-0001-6755-791X
  • Lorenzo, Lazaro|||0000-0001-6648-8684
  • Bizien, Lucy|||0000-0001-9163-9122
  • Trouillet-Assant, Sophie|||0000-0001-6439-4705
  • Dobbs, Kerry|||0000-0002-3432-3137
  • Almeida de Jesus, Adriana
  • Belot, Alexandre|||0000-0003-4902-5332
  • Kallaste, Anne|||0000-0002-7492-667X
  • Catherinot, Emilie
  • Tandjaoui-Lambiotte redondo, Yacine|||0000-0003-1123-4788
  • Le Pen, Jérémie|||0000-0001-7025-9526
  • Kerner, Gaspard|||0000-0003-0146-9428
  • Bigio, Benedetta|||0000-0001-7291-5638
  • Seeleuthner, Yoann|||0000-0002-1878-8567
  • Yang, Rui|||0000-0003-4427-2158
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Spaan, András|||0000-0001-5981-7259
  • Delmonte, Ottavia M.
  • Abers, Michael S.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Casari, Giorgio|||0000-0002-0115-8980
  • Lampasona, Vito|||0000-0001-5162-8445
  • Piemonti, Lorenzo|||0000-0002-2172-2198
  • Ciceri, Fabio|||0000-0003-0873-0123
  • Bilguvar, Kaya|||0000-0002-7313-7652
  • Lifton, Richard P.
  • Vasse, Marc
  • Smadja, David M.
  • Migaud, Mélanie|||0000-0003-3062-1214
  • Hadjadj, Jérome|||0000-0002-2520-3272
  • Terrier, Benjamin|||0000-0001-6612-7336
  • Duffy, Darragh|||0000-0002-8875-2308
  • Quintana-Murci, Lluis|||0000-0003-2429-6320
  • van de Beek, Diederik|||0000-0002-4571-044X
  • Roussel, Lucie|||0000-0001-5355-702X
  • Vinh, Donald C.|||0000-0003-1347-7767
  • Tangye, Stuart|||0000-0002-5360-5180
  • Haerynck, Filomeen|||0000-0001-9161-7361
  • Dalmau, David|||0000-0003-1936-478X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Brodin, Petter|||0000-0002-8103-0046
  • Nussenzweig, Michel|||0000-0003-0592-8564
  • Boisson-Dupuis, Stephanie|||0000-0002-7115-116X
  • Rodríguez-Gallego, Carlos|||0000-0002-4344-8644
  • Vogt, Guillaume
  • Mogensen, Trine Hyrup|||0000-0002-1853-9704
  • Oler, Andrew J.|||0000-0002-6310-0434
  • Gu, Jingwen
  • Burbelo, Peter D.|||0000-0003-1717-048X
  • Cohen, Jeffrey I.|||0000-0003-0238-7176
  • Biondi, Andrea
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Rossignol, Patrick
  • Mayaux, Julien
  • Rieux-Laucat, Frédéric|||0000-0001-7858-7866
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Fusco, Francesca
  • Ursini, Matilde Valeria
  • Imberti, Luisa|||0000-0002-2075-8391
  • Sottini, Alessandra
  • Paghera, Simone
  • Quiros-Roldan, Eugenia
  • Rossi, Camillo
  • Castagnoli, Riccardo|||0000-0003-0029-9383
  • Montagna, Daniela
  • Licari, Amelia|||0000-0002-1773-6482
  • Marseglia, Gian Luigi|||0000-0003-3662-0159
  • Duval, Xavier
  • Ghosn, Jade
  • Tsang, John S.|||0000-0003-3186-3047
  • Goldbach-Mansky, Raphaela|||0000-0001-7865-5769
  • Kisand, Kai|||0000-0002-5426-4648
  • Lionakis, Michail S.
  • Puel, Anne|||0000-0003-2603-0323
  • Zhang, Shein-Ying
  • Holland, Steven|||0000-0003-3207-5464
  • Gorochov, Guy|||0000-0003-2097-9677
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Rice, Charles M.|||0000-0003-3087-8079
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Notarangelo, Luigi|||0000-0002-8335-0262
  • Abel, Laurent|||0000-0001-7016-6493
  • Su, Helen C.|||0000-0002-5582-9110
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

  • Zhang, Qian|||0000-0002-9040-3289
  • Bastard, Paul|||0000-0002-5926-8437
  • Liu, Zhiyong|||0000-0002-6930-5879
  • Le Pen, Jérémie|||0000-0001-7025-9526
  • Moncada-Velez, Marcela|||0000-0002-3073-5345
  • Chen, Jie|||0000-0002-5354-4170
  • Ogishi, Masato|||0000-0003-2421-7389
  • Sabli, Ira K. D.|||0000-0002-0170-2990
  • Hodeib, Stephanie|||0000-0002-5978-6189
  • Korol, Cecilia|||0000-0002-0023-8823
  • Rosain, Jérémie|||0000-0002-2822-161X
  • Bilguvar, Kaya|||0000-0002-7313-7652
  • Ye, Junqiang
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bigio, Benedetta|||0000-0001-7291-5638
  • Yang, Rui|||0000-0003-4427-2158
  • Arias, Andrés Augusto|||0000-0002-9478-8403
  • Zhou, Qinhua|||0000-0002-5112-3727
  • Zhang, Yu|||0000-0002-0332-0013
  • Onodi, Fanny
  • Korniotis, Sarantis
  • Karpf, Léa
  • Philippot, Quentin
  • Chbihi, Marwa|||0000-0002-2771-851X
  • Bonnet-Madin, Lucie|||0000-0002-9848-3287
  • Dorgham, Karim|||0000-0001-9539-3203
  • Smith, Nikaïa|||0000-0002-0202-612X
  • Schneider, William M.|||0000-0001-9407-6118
  • Razooky, Brandon S.|||0000-0002-5263-1512
  • Hoffmann, Hans-Heinrich|||0000-0003-0554-0244
  • Michailidis, Eleftherios|||0000-0002-9907-4346
  • Moens, Leen
  • Han, Ji Eun|||0000-0003-1112-9320
  • Lorenzo, Lazaro|||0000-0001-6648-8684
  • Bizien, Lucy|||0000-0001-9163-9122
  • Meade, Philip|||0000-0002-6754-7209
  • Neehus, Anna-Lena|||0000-0002-8573-6820
  • Ugurbil, Aileen Camille|||0000-0002-9450-3092
  • Corneau, Aurélien
  • Kerner, Gaspard|||0000-0003-0146-9428
  • Zhang, Peng|||0000-0002-6129-567X
  • Rapaport, Franck|||0000-0001-6553-2110
  • Seeleuthner, Yoann|||0000-0002-1878-8567
  • Manry, Jeremy|||0000-0001-5998-2051
  • Masson, cecile|||0000-0001-7870-7821
  • Schmitt, Yohann
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Le Voyer, Tom|||0000-0002-7253-3135
  • Khan, Taushif|||0000-0002-7917-8965
  • Li, Juan|||0000-0002-1617-3294
  • Fellay, Jacques|||0000-0002-8240-939X
  • Roussel, Lucie|||0000-0001-5355-702X
  • Shahrooei, Mohammad
  • Alosaimi, Mohammed F.
  • Mansouri, Davood
  • Al-Saud, Haya
  • Al-Mulla, Fahd|||0000-0001-5409-3829
  • Almourfi, Feras|||0000-0002-5166-4662
  • Al-Muhsen, Saleh Zaid
  • Alsohime, Fahad|||0000-0002-4979-3895
  • Al Turki, Saeed|||0000-0001-7017-336X
  • Hasanato, Rana|||0000-0002-4697-2222
  • van de Beek, Diederik|||0000-0002-4571-044X
  • Biondi, Andrea
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Imberti, Luisa|||0000-0002-2075-8391
  • Sottini, Alessandra
  • Paghera, Simone
  • Quiros-Roldan, Eugenia
  • Rossi, Camillo
  • Oler, Andrew J.|||0000-0002-6310-0434
  • Tompkins, Miranda F.|||0000-0003-2941-7515
  • Alba, Camille|||0000-0002-0458-1629
  • Vandernoot, Isabelle
  • Goffard, Jean-Christope
  • Smits, Guillaume|||0000-0003-2845-6758
  • Migeotte, Isabelle
  • Haerynck, Filomeen|||0000-0001-9161-7361
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Morange, Pierre-Emmanuel|||0000-0002-9065-722X
  • Keles, Sevgi|||0000-0001-7344-8947
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Kadriye, Kart Yaşar|||0000-0003-2963-4894
  • Senoglu, Sevtap|||0000-0003-4796-9583
  • Karabela, Şemsi Nur|||0000-0003-2562-3004
  • Rodríguez-Gallego, Carlos|||0000-0002-4344-8644
  • Novelli, Giuseppe|||0000-0002-7781-602X
  • Hraiech, Sami
  • Tandjaoui-Lambiotte redondo, Yacine|||0000-0003-1123-4788
  • Duval, Xavier
  • Laouénan, Cédric|||0000-0002-3681-6314
  • Foti, Giuseppe
  • Bellani, Giacomo
  • Citerio, Giuseppe|||0000-0002-5374-3161
  • Contro, Ernesto
  • Pesci, Alberto
  • Valsecchi, Maria Grazia
  • Cazzaniga, Marina
  • Abad Capa, Jorge|||0000-0002-8129-7859
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • Akcan, Ozge Metin
  • Darazam, Ilad Alavi
  • Aldave, Juan C.
  • Ramos, Miquel Alfonso
  • Nadji, Seyed Alireza
  • Alkan, Gulsum
  • Allardet-Servent, Jerome
  • Allende-Martinez, Luis M.
  • Alsina Manrique, Laia|||0000-0002-3559-0018
  • Alyanakian, Marie-Alexandra
  • Amador Borrero, Blanca|||0000-0001-6170-8721
  • Amoura, Zahir
  • Antolí, Arnau
  • Arslan, Sevket
  • Assant, Sophie
  • Auguet, Teresa
  • Azot, Axelle
  • Bajolle, Fanny
  • Baldolli, Aurélie
  • Ballester, Maite
  • Feldman, Hagit Baris
  • Barrou, Benoit
  • Beurton, Alexandra
  • Bilbao, Agurtzane
  • Blanchard-Rohner, Geraldine
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Blandinières, Adeline
  • Blázquez-Gamero, Daniel|||0000-0001-6483-8329
  • Bloomfield, Marketa
  • Bolivar-Prados, Mireia|||0000-0002-8896-1150
  • Borie, Raphael
  • Bosteels, Cédric
  • Bousfiha, Ahmed A.
  • Bouvattier, Claire
  • Boyarchuk, Oksana|||0000-0002-1234-0040
  • Bueno, Maria Rita P.
  • Cáceres Agra, Juan José|||0000-0001-9003-261X
  • Calimli, Semra
  • Capra, Ruggero
  • Carrabba, Maria
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Caseris, Marion
  • Castelle, Martin
  • Castelli, Francesco|||0000-0001-9161-7804
  • Castillo de Vera, Martín
  • Castro, Mateus V.
  • Catherinot, Emilie
  • Chalumeau, Martin
  • Charbit, Bruno
  • Cheng, Matthew P.
  • Clavé i Civit, Pere|||0000-0002-0696-8560
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Codina, Anna
  • Colkesen, Fatih
  • Çölkesen, Fatma|||0000-0001-9545-5179
  • Comarmond, Cloé
  • Dalmau, David|||0000-0003-1936-478X
  • Darley, David Ross|||0000-0002-9721-101X
  • Dauby, Nicolas
  • Dauger, Stéphane
  • de Pontual, Loic
  • Dehban, Amin
  • Delplancq, Geoffroy
  • Demoule, Alexandre
  • Diehl, Jean-Luc
  • Dobbelaere, Stephanie
  • Durand, Sophie
  • Eldars, Waleed
  • Elgamal, Mohamed
  • Elnagdy, Marwa H.
  • Emiroglu, Melike|||0000-0003-1307-0246
  • Erdeniz, Emine Hafize
  • Erol Aytekin, Selma
  • Euvrard, Romain
  • Evcen, Recep
  • Fabio, Giovanna
  • Faivre, Laurence
  • Falck, Antonin
  • Fartoukh, Muriel
  • Faure, Morgane
  • Fernández Arquero, Miguel
  • Flores, Carlos|||0000-0001-5352-069X
  • Francois, Bruno
  • Fumadó, Victoria
  • Fusco, Francesca
  • García Solis, Blanca|||0000-0002-3718-2560
  • Gaussem, Pascale
  • Gil-Herrera, Juana|||0000-0002-2297-9665
  • Gilardin, Laurent|||0000-0001-9212-0859
  • Girona-Alarcón, Mònica|||0000-0002-2752-7481
  • Gok, Funda
  • González Montelongo, Rafaela|||0000-0001-9022-8663
  • Guerder, Antoine
  • Gul, Yahya
  • Guner, Sukru Nail
  • Gut, Marta|||0000-0002-4063-7159
  • Hadjadj, Jérôme
  • Halwani, Rabih|||0000-0002-6516-7771
  • Hammarström, Lennart|||0000-0002-8635-9609
  • Nevin, Hatipoglu
  • Hernandez-Brito, Elisa|||0000-0002-8435-6885
  • Heijmans, Cathérine
  • Holanda-Peña, María Soledad
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
  • Hoste, Levi
  • Hoste, Eric
  • Humbert, Linda
  • Iglesias, Alejandro D.
  • Íñigo-Campos, Antonio|||0000-0003-1571-0454
  • Jamme, Matthieu
  • Arranz, María Jesús|||0000-0002-6757-9198
  • Jordán García, Iolanda|||0000-0002-2041-4425
  • Jorens, Philippe
  • Kanat, Fikret
  • Kapakli, Hasan
  • Kara, Iskender
  • Karbuz, Adem
  • Kendir Demirkol, Yasemin
  • Klocperk, Adam
  • Król, Zbigniew J.
  • Kuentz, Paul
  • Kwan, Mike Yat Wah|||0000-0002-1476-9625
  • Lagier, Jean-Christophe
  • Lambrecht, Bart N.
  • Lau, Yu Lung|||0000-0002-4780-0289
  • Le Bourgeois, Fleur
  • Leo, Yee-Sin
  • Leon Lopez, Rafael|||0000-0002-8102-9520
  • Leung, Daniel|||0000-0002-9360-6233
  • Levin, Michael|||0000-0003-2767-6919
  • Levy, Michael
  • Lévy, Romain
  • Li, Zhi
  • Linglart, Agnès|||0000-0003-3455-002X
  • Loeys, Bart
  • Lorenzo-Salazar, José Miguel|||0000-0002-5135-2861
  • Louapre, Céline
  • Lubetzki, Catherine
  • Luyt, Charles-Edouard|||0000-0001-7424-2705
  • Lye, David C.
  • Marjani, Majid
  • Marquez Pereira, Jesús
  • Martínez Pueyo, David
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Marzana, Iciar
  • Mathian, Alexis|||0000-0002-7653-6528
  • Matos, Larissa R. B.
  • Matthews, Gail V.
  • Mayaux, Julien
  • Mège, Jean-Louis
  • Melki, Isabelle
  • Meritet, Jean-François
  • Meyts, Isabelle|||0000-0003-1214-0302
  • Mezidi, Mehdi
  • Millereux, Maude
  • Mirault, Tristan
  • Mircher, Clotilde
  • Mirsaeidi, Mehdi
  • Montesdeoca Melián, Abián|||0000-0002-9158-2127
  • Morales Martínez, Antonio
  • Mordacq, Clémence
  • Morelle, Guillaume|||0000-0001-6511-1674
  • Mouly, Stéphane
  • Muñoz-Barrera, Adrián|||0000-0002-1561-5898
  • Naesens, Leslie
  • Nafati, Cyril
  • Farela Neves, João
  • FP. Ng, Lisa|||0000-0003-4071-5222
  • Novoa Medina, Yeray|||0000-0002-9564-0654
  • Nuñez Cuadros, Esmeralda|||0000-0003-1938-1678
  • Ocejo-Vinyals, J. Gonzalo|||0000-0003-2245-4639
  • Orbak, Zerrin
  • Oualha, Mehdi
  • Pan-Hammarström, Qiang|||0000-0003-1990-8804
  • Parizot, Christophe
  • Pascreau, Tiffany
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Pellegrini, Sandra
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Philippe, Aurélien
  • Planas-Serra, Laura|||0000-0002-2586-0897
  • Ploin, Dominique
  • Poissy, Julien|||0000-0001-6017-5353
  • Poncelet, Géraldine
  • Pouletty, Marie
  • Quentric, Paul
  • Raoult, Didier
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Reisli, Ismail
  • Ricart, Pilar|||0000-0003-0067-9132
  • Richard, Jean-Christophe
  • Rivet, Nadia
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Rocamora Blanch, Gemma|||0000-0003-4427-9384
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Romero, Carolina Soledad|||0000-0002-2325-4463
  • Rothenbuhler, Anya
  • Rozenberg, Flore|||0000-0001-7212-2021
  • Ruiz del Prado, María Yolanda
  • Sabater-Riera, Joan|||0000-0003-1246-5537
  • Sánchez, Oliver
  • Sánchez Ramón, Silvia|||0000-0001-9585-6167
  • Schmidt, Matthieu|||0000-0002-2931-4412
  • Schweitzer, Cyril E.
  • Scolari, Francesco
  • Sediva, Anna
  • Seijo, Luis M.
  • Sene, Damien
  • Seppänen, Mikko R. J.|||0000-0001-9733-3650
  • Serra Ilovich, Alex
  • Shahrooei, Mohammed
  • Slabbynck, Hans
  • Smadja, David M.
  • Sobh, Ali
  • Solanich, Xavier|||0000-0002-2572-2187
  • Dalgard, Clifton L.|||0000-0003-2025-8239
  • Milner, Joshua D.
  • Vinh, Donald C.|||0000-0003-1347-7767
  • Mogensen, Trine Hyrup|||0000-0002-1853-9704
  • Marr, Nico|||0000-0002-1927-7072
  • Spaan, András|||0000-0001-5981-7259
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Boisson-Dupuis, Stephanie|||0000-0002-7115-116X
  • Bustamante, Jacinta|||0000-0002-3439-2482
  • Puel, Anne|||0000-0003-2603-0323
  • Ciancanelli, Michael J.|||0000-0002-4623-852X
  • Maniatis, Tom|||0000-0002-2722-8633
  • Soumelis, Vassili
  • Amara, Ali
  • Nussenzweig, Michel|||0000-0003-0592-8564
  • Garcia-Sastre, Adolfo|||0000-0002-6551-1827
  • Krammer, Florian|||0000-0003-4121-776X
  • Pujol, Aurora|||0000-0002-9606-0600
  • Duffy, Darragh|||0000-0002-8875-2308
  • Lifton, Richard P.
  • Zhang, Shen-Ying|||0000-0002-9449-3672
  • Gorochov, Guy|||0000-0003-2097-9677
  • Béziat, Vivien|||0000-0002-4020-824X
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Sancho Shimizu, Vanessa|||0000-0002-3519-0727
  • Rice, Charles M.|||0000-0003-3087-8079
  • Abel, Laurent|||0000-0001-7016-6493
  • Notarangelo, Luigi|||0000-0002-8335-0262
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Su, Helen C.|||0000-0002-5582-9110
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Zhang, S. Y.
  • Blanch, G. R.
  • Riera, J. S.
  • Ballester Devis, Maria|||0000-0002-5413-4640
  • van Braeckel, E.
  • Vincent, Amy|||0000-0002-0360-6644
  • Zatz, Mayana|||0000-0003-3970-8025
  • Vélez-Santamaria, V.
  • Toubiana, J.
  • Vilaire, M. E.
  • Ursini, Matilde Valeria
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Van Den Rym, Ana
  • Yosunkaya, A.
  • Thy, M.
  • van Agtmael, Michiel
  • Bomers, Marije
  • Chouchane, Osoul
  • Geerlings, Suzanne
  • Goorhuis, Bram
  • Grobusch, Martin P.
  • Harris, Vanessa
  • Hermans, Sabine M.
  • Hovius, Joppe W.
  • Nellen, Jeaninne
  • Peters, Edgar
  • van der Poll, Tom
  • Prins, Jan M.
  • Reijnders, Tom
  • Schinkel, Michiel
  • Sigaloff, Kim
  • Stijnis, Cornelis S.
  • van der Valk, Marc
  • van Vugt, Michèle
  • Joost Wiersinga, W.
  • Algera, Anna Geke
  • van Baarle, Frank
  • Bos, Lieuwe D.|||0000-0003-2911-4549
  • Botta, Michela
  • de Bruin, Sanne
  • Bulle, Esther
  • Elbers, Paul
  • Fleuren, Lucas
  • Girbes, Armand
  • Hagens, Laura
  • Heunks, Leo
  • Horn, Janneke
  • van Mourik, Niels
  • Paulus, Frederique
  • Raasveld, Jorinde
  • Schultz, Marcus J.|||0000-0003-3969-7792
  • Smit, Marry
  • Stilma, Willemke|||0000-0002-7581-1321
  • Thoral, Patrick
  • Tsonas, Anissa M.
  • de Vries, Heder
  • Bax, Diane
  • Cloherty, Alex
  • Beudel, Martijn
  • Brouwer, Matthijs C.
  • Koning, Rutger|||0000-0003-3128-5072
  • Bogaard, H. J.
  • de Brabander, J.
  • de Bree, G.
  • Bugiani, Marianna
  • Geerts, Bart
  • Hollmann, Markus W.
  • Preckel, Benedikt
  • Veelo, Denise
  • Geijtenbeek, Theo
  • Hafkamp, Florianne
  • Hamann, Jorg
  • Hemke, Robert
  • de Jong, Menno D.
  • Schuurman, Alex
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Vlaar, Alexander P. J.
  • Wouters, Dorien
  • Zwinderman, Aeilko Having Koos
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Muhsen, Saleh Al
  • Anderson, Mark S.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Itan, Yuval
  • Cirulli, Elizabeth
  • Barrett, Kelly Schiabor
  • Washington, Nicole
  • Bondarenko, Anastasiia
  • Brodin, Petter|||0000-0002-8103-0046
  • Bryceson, Yenan
  • Bustamante, Carlos D.|||0000-0002-4187-7920
  • Butte, Manish J.
  • Casari, Giorgio|||0000-0002-0115-8980
  • Chakravorty, Samya|||0000-0002-0236-3281
  • Christodoulou, John
  • Le Mestre, S.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cooper, Megan A.
  • David, Alessia
  • DeRisi, Joseph L.
  • Desai, Murkesh
  • Drolet, Beth A.
  • Espinosa, Sara
  • Franco, Jose Luis
  • Gregersen, Peter K.|||0000-0003-1613-1518
  • Hagin, David|||0000-0003-2702-1031
  • Heath, Jim
  • Henrickson, Sarah E.
  • Hsieh, Elena
  • Imai, Kohsuke
  • Karamitros, Timokratis
  • Kisand, Kai|||0000-0002-5426-4648
  • Ku, Cheng-Lung
  • Ling, Yun
  • Lucas, Carrie L.
  • Marodi, Laszlo
  • Mironska, Kristina
  • Morio, Tomohiro
  • Novelli, Antonio
  • O'Farrelly, Cliona
  • Okada, Satoshi|||0000-0002-4622-5657
  • Planas, Anna Maria|||0000-0002-6147-1880
  • Prando, Carolina|||0000-0002-9570-9770
  • Quintana-Murci, Lluis|||0000-0003-2429-6320
  • Renia, Laurent
  • Renieri, Alessandra|||0000-0002-0846-9220
  • Sankaran, Vijay
  • Snow, Andrew|||0000-0002-8728-6691
  • Tangye, Stuart|||0000-0002-5360-5180
  • Turvey, Stuart
  • Uddin, Furkan
  • Uddin, Mohammed J.
  • Vazquez, Sara E.
  • von Bernuth, Horst
  • Zawadzki, Pawel
  • Jing, Huie|||0000-0001-6283-3452
  • Tung, W.
  • Meguro, K.
  • Shaw, E.
  • Tung, Wesley|||0000-0002-4577-3926
  • Shafer, S.
  • Zheng, L.
  • Zhang, Z.
  • Kubo, S.
  • Chauvin, S. D.
  • Shaw, Elana|||0000-0001-9265-8026
  • Lenardo, M.
  • Luthers, Christopher R.
  • Bauman, Bradly M.
  • Shafer, Samantha
  • Zheng, Lixin
  • Zhang, Zinan
  • Kubo, Satoshi
  • Chauvin, Samuel D.
  • Lenardo, Michael
  • Lack, Justin
  • Karlins, Eric
  • Hupalo, Daniel M.
  • Rosenberger, John
  • Sukumar, Gauthaman
  • Wilkerson, Matthew D.
  • Zhang, Xijun
Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PROSHADE Protocol, Designing and Evaluating a Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer: A Mix-Method Study

  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
  • Parker, Lucy Anne
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Mira-Bernabeu, Javier
  • Gómez-Pérez, Luis|||0000-0003-1396-0484
  • Caballero-Romeu, Juan-Pablo|||0000-0002-5737-6047
  • Pertusa-Martínez, Salvador|||0000-0002-2990-5570
  • Cebrián-Cuenca, Ana M.|||0000-0003-3710-6370
  • Moral Peláez, Irene|||0000-0002-3842-8796
  • López-Garrigós, Maite
  • Canelo Aybar, Carlos Gilberto|||0000-0002-0844-4365
  • Ronda Pérez, Elena|||0000-0003-1886-466X
  • Guilabert, Mercedes|||0000-0002-0706-9911
  • Prieto-González, Antonio
  • Hernández-Aguado, Ildefonso
Background: Opportunistic prostate-specific antigen (PSA) screening may reduce prostate cancer mortality risk but is associated with false positive results, biopsy complications and overdiagnosis. Although different organisations have emphasised the importance of shared decision making (SDM) to assist men in deciding whether to undergo prostate cancer screening, recent evaluations show that the available decision aids fail to facilitate SDM, mainly because they do not consider the patients' perspective in their design. We aim to systematically develop and test a patient decision aid to promote SDM in prostate cancer screening, following the Knowledge to Action framework. Methods: (1) Feasibility study: a quantitative survey evaluating the population and clinician (urologists and general practitioners) knowledge of the benefits and risks derived from PSA determination and the awareness of the available recommendations. Focus groups to explore the challenges patients and clinicians face when discussing prostate cancer screening, the relevance of a decision aid and how best to integrate it into practice. (2) Patient decision aid development: Based on this data, an evidence-based multicomponent SDM patient decision aid will be developed. (3) User-testing: an assessment of the prototype of the initial patient decision aid through a user-testing design based on mix-methods (questionnaire and semi-structured review). The decision aid will be refined through several iterative cycles of feedback and redesign. (4) Validation: an evaluation of the patient decision aid through a cluster-randomised controlled trial. Discussion: The designed patient decision aid will provide balanced information on screening benefits and risks and should help patients to consider their personal preferences and to take a more active role in decision making. Conclusions: The well-designed patient decision aid (PDA) will provide balanced information on screening benefits and risks and help patients consider their personal preferences.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç
  • Bystrup, Sara
  • Cabrero-de Las Heras, Sara
  • Musulén, Eva
  • Palomero, Luis
  • Henar Alonso, Maria
  • Arango Corro, Diego
  • Nieto Raya, Rocio
Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker, Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo, Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu, In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease., This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.